Contrasting XBiotech (NASDAQ:XBIT) and Mosaic ImmunoEngineering (OTCMKTS:CPMV)

XBiotech (NASDAQ:XBIT) and Mosaic ImmunoEngineering (OTCMKTS:CPMV) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.

Profitability

This table compares XBiotech and Mosaic ImmunoEngineering’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-26.10%	-25.06%
Mosaic ImmunoEngineering	N/A	N/A	-1,908.81%

Volatility and Risk

XBiotech has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Mosaic ImmunoEngineering has a beta of -0.84, meaning that its stock price is 184% less volatile than the S&P 500.

Institutional & Insider Ownership

55.7% of XBiotech shares are owned by institutional investors. 30.8% of XBiotech shares are owned by insiders. Comparatively, 81.0% of Mosaic ImmunoEngineering shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares XBiotech and Mosaic ImmunoEngineering”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	N/A	N/A	-$45.54 million	($1.32)	-1.78
Mosaic ImmunoEngineering	N/A	N/A	-$690,000.00	($0.09)	-7.49

Mosaic ImmunoEngineering is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for XBiotech and Mosaic ImmunoEngineering, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	1	0	0	0	1.00
Mosaic ImmunoEngineering	0	0	0	0	0.00

Summary

XBiotech beats Mosaic ImmunoEngineering on 5 of the 9 factors compared between the two stocks.

About XBiotech

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

About Mosaic ImmunoEngineering

Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.